Abstract:Myeloid neoplasms (MN) are neoplastic diseases caused by the clonal proliferation of myeloid cells, which usually involve the bone marrow and affect blood cells, thus affecting the functions of other systems and even leading to short-term death. The diagnosis of MN is complicated, mainly relying on the World Health Organization (WHO) tumor classification. [ 1 , 2 ] Next-generation sequencing (NGS), as a high-throughput technology, can sequence DNA or RNA quickly and cost-effectively, making it suitable for simultaneous detection of multiple genetic abnormalities in MN. The sequence variants/mutations it detects are widely used in MN diagnosis, prognosis, treatment decisions, and patient follow-up. [ 3 ] Since the publication of the revised 4th edition of the WHO classification of hematolymphoid tumors (WHO-HAEM4R) in 2016, NGS mutation analysis has become common in clinical practice. The basis for MN classification continues to evolve as new pathological features are discovered and new therapies become available. Therefore, the World Health Organization released the fifth edition of the World Health Organization Classification of Hemolymph Neoplasms (WHO-HAEM5) on June 22, 2022. [ 4 ] Shortly thereafter, the Clinical Advisory Committee launched the International Consensus Classification (ICC) of hematologic neoplasms. [ 5 ] The ICC classification of specific MN categories was then introduced in detail, such as acute myeloid leukemia (AML), [ 6 ] myelodysplastic syndrome (MDS), [ 7 ] myeloproliferative neoplasm (MPN), [ 8 ] myelodysplasia/myeloproliferative neoplasms (MDS)/MPN), [ 9 ] published in Virchows Arch. Therefore, WHO-HAEM4R was updated to 2 different versions at the same time. There are inevitably differences between the 2, and both the classification algorithm and the classification results need to be fully understood. [ 10 ] To this end, we used WHO-HAEM5 and ICC to reclassify MN cases previously diagnosed according to WHO-HAEM4R to explore the practical significance of these 2 latest classification systems. We endeavored to carefully examine the contribution of these NGS-detected mutation signatures to both classifications. This is very useful for everyone to understand the different effects of the 2 new classifications in practical applications.

Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5

Genetic studies in clonal haematopoiesis, myelodysplastic neoplasms and acute myeloid leukaemia – a practical guide to WHO-HAEM5

Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms – a practical guide to WHO HAEM5

Overview on WHO-HAEM5 and the diagnostic relevance of genetic alterations for the classification

Genetic alterations in lymphoblastic leukaemia / lymphoma – a practical guide to WHO HAEM5

Genetic alterations in mature B- and T-cell lymphomas – a practical guide to WHO-HAEM5

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

Advances in understanding and management of myeloproliferative neoplasms

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable

NGS panel enhance precise diagnosis of myeloid neoplasms under WHO-HAEM5 and International Consensus Classification: An observational study

Pathogenesis and management of high molecular risk myeloproliferative neoplasms

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase

Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome

Advances in molecular evaluation of myeloproliferative neoplasms

Evolution of myeloproliferative neoplasms from normal blood stem cells

The Current and Future Treatment Landscape

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms

The Fifth Edition of the World Health Organization Classification and the International Consensus Classification of Myeloid Neoplasms: Evolving Guidelines in the Molecular Era with Practical Implications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Classification and Prognostic Stratification Based on Genomic Features in Myelodysplastic and Myeloproliferative Neoplasm- and Their Overlapping Conditions